You searched for Cybin - Page 49 of 60

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’

Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research The Vancouver-based company was formed in 2019 as the ‎first psychedelic umbrella platform The Delic self-sustaining Ecosystem covers three main areas: media, health, and science On March 4, 2021, Delic announced its … Continue reading “Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’”

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Co-Founder, CEO Featured on Bell2Bell Podcast

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted … Continue reading “QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Co-Founder, CEO Featured on Bell2Bell Podcast”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space”

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Keynote Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Laura Dawn, Msc. will serve as one of the headlining speakers at Meet Delic on Nov. 6, 2021. According to the update, her keynote, “Exploring the Intersection Between Psychedelics & Creative Problem Solving,” targets business and thought-leaders, entrepreneurs and creators. “Laura … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Keynote Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast

Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders Greg also shared the challenges that the industry is facing currently, mostly to do with … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast”

QualityStocksNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Scientific Advisor Granted Full Professorship

Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced that Glenn Sammis, a professor and scientific advisor to subsidiary Delic Labs, has received a full professorship at the University of British Columbia in the chemistry department. The announcement also noted that Sammis will be working closely with Dr. Markus Roggen in developing intellectual property (“IP”) … Continue reading “QualityStocksNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Scientific Advisor Granted Full Professorship”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research Center at … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day”

Site Search

Company Search

Search Results for: Cybin